EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY

被引:34
作者
Calvo, Pilar [1 ,2 ]
Ferreras, Antonio [1 ,2 ]
Al Adel, Fadwa [3 ]
Dangboon, Wantanee [4 ]
Brent, Michael H. [5 ]
机构
[1] Miguel Servet Univ Hosp, Ophthalmol Dept, IIS Aragon, Zaragoza, Spain
[2] Univ Zaragoza, Zaragoza, Spain
[3] Princess Nourah Bint Abdulrahman Univ, Dept Ophthalmol, Riyadh, Saudi Arabia
[4] Prince Songkla Univ, Dept Ophthalmol, Fac Med, Hat Yai, Songkhla, Thailand
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2018年 / 38卷 / 03期
关键词
diabetes; cataract; diabetic macular edema; optical coherence tomography; dexamethasone; intravitreal; TRIAMCINOLONE ACETONIDE; RISK-FACTORS; ANTI-VEGF; PHARMACOKINETICS; RETINOPATHY; PROGRESSION; INJECTION; EFFICACY; SYSTEM; TRIAL;
D O I
10.1097/IAE.0000000000001552
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 mu g; Allergan) administered immediately after cataract surgery in diabetic patients. Methods: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. Results: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 +/- 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 mu m (95% confidence interval, 227.5-254.6 mu m) at baseline to 236.9 mu m (95% confidence interval, 223.9-249.9 mu m) at 1 week (P = 0.09), 238.9 mu m (95% confidence interval, 225.5-252.3 mu m) at 1 month (P = 0.44), and 248 mu m (95% confidence interval, 232.4-260.8 mu m) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 mu m in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure >= 22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. Conclusion: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients.
引用
收藏
页码:490 / 496
页数:7
相关论文
共 38 条
[1]   Dexamethasone Intravitreal Implant During Phacoemulsification [J].
Agarwal, Aniruddha ;
Gupta, Vishali ;
Ram, Jagat ;
Gupta, Amod .
OPHTHALMOLOGY, 2013, 120 (01) :211-U272
[2]  
[Anonymous], 2013, IDF DIAB ATL
[3]   Lutein prevents cataract development and progression in diabetic rats [J].
Arnal, Emma ;
Miranda, Maria ;
Almansa, Inmaculada ;
Muriach, Maria ;
Barcia, Jorge M. ;
Romero, Francisco J. ;
Diaz-Llopis, Manuel ;
Bosch-Morell, Francisco .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (01) :115-120
[4]   Macular Edema After Cataract Surgery in Eyes Without Preoperative Central-Involved Diabetic Macular Edema [J].
Baker, Carl W. ;
Almukhtar, Talat ;
Bressler, Neil M. ;
Glassman, Adam R. ;
Grover, Sandeep ;
Kim, Stephen J. ;
Murtha, Timothy J. ;
Rauser, Michael E. ;
Stockdale, Cynthia .
JAMA OPHTHALMOLOGY, 2013, 131 (07) :870-879
[5]   Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: Functional and anatomic results [J].
Boscia, F ;
Furino, C ;
Dammacco, R ;
Ferreri, P ;
Sborgia, L ;
Sborgia, C .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2005, 15 (01) :89-95
[6]   Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema [J].
Boyer, David S. ;
Yoon, Young Hee ;
Belfort, Rubens, Jr. ;
Bandello, Francesco ;
Maturi, Raj K. ;
Augustin, Albert J. ;
Li, Xiao-Yan ;
Cui, Harry ;
Hashad, Yehia ;
Whitcup, Scott M. .
OPHTHALMOLOGY, 2014, 121 (10) :1904-1914
[7]   Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema [J].
Cervera, E. ;
Diaz-Llopis, M. ;
Udaondo, P. ;
Garcia-Delpech, S. .
EYE, 2008, 22 (09) :1180-1182
[8]   Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation [J].
Chan, Alfred W. H. ;
Ho, Ye-shih ;
Chung, Sookja K. ;
Chung, Stephen S. M. .
EXPERIMENTAL EYE RESEARCH, 2008, 87 (05) :454-461
[9]   Risk factors for steroid response among cataract patients [J].
Chang, David F. ;
Tan, Jeffrey J. ;
Tripodis, Yorghos .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2011, 37 (04) :675-681
[10]   Pharmacokinetics of a Sustained-Release Dexamethasone Intravitreal Implant in Vitrectomized and Nonvitrectomized Eyes [J].
Chang-Lin, Joan-En ;
Burke, James A. ;
Peng, Qing ;
Lin, Ton ;
Orilla, Werhner C. ;
Ghosn, Corine R. ;
Zhang, Kai-Ming ;
Kuppermann, Baruch D. ;
Robinson, Michael R. ;
Whitcup, Scott M. ;
Welty, Devin F. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (07) :4605-4609